查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926898

碘化油注射市場依給藥途徑、給藥頻率、包裝、用途、最終用戶和通路分類－2026-2032年全球預測

Iodized Oil Injection Market by Administration Route, Product Variant, Packaging, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年碘化油注入市場價值為8,424萬美元，預計到2026年將成長至9,606萬美元，年複合成長率為12.17%，到2032年將達到1.8826億美元。

關鍵市場統計數據
基準年 2025 8424萬美元
預計年份：2026年 9606萬美元
預測年份 2032 1.8826億美元
複合年成長率 (%) 12.17%

本文說明了碘化油注射的臨床用途、發展歷程、安全重點、生產注意事項以及當今的臨床意義。

碘化油注射在診斷影像和標靶治療介入的交叉領域佔據著獨特的地位，其作用隨著影像技術和介入醫學的進步而不斷演變。碘化油注射最初用作滲透性的造影劑，以增強肝臟和淋巴結構的顯影。然而，其藥物動力學特性和放射密度特徵表明，它不僅可以作為造影劑，還可以作為局部治療藥物的載體。臨床醫生和供應鏈相關人員必須了解其臨床效用、給藥方案、安全性考量和生產規範之間的相互作用，才能指導其應用和採購決策。

重大的技術、監管和物流變革重新定義了碘油輸注的臨床預期、供應彈性和產品創新。

在技​​術創新、監管調整和服務提供體系轉變的推動下，碘油注射領域正發生許多變革，重塑著產業格局。斷層掃描和介入影像技術的進步，提高了人們對高解析度造影劑和可預測分佈特性的期望，促使人們更加關注產品的純度、顆粒行為以及與輔助介入設備的兼容性。因此，生產商和臨床使用者都在優先考慮能夠支援更安全、更精準給藥的配方和包裝。

評估近期美國關稅措施對籌資策略、庫存彈性和供應商多元化的累積營運和採購影響

近期關稅政策和貿易措施對整個醫療產品供應鏈產生了連鎖反應，影響了採購決策、價格談判動態和區域製造策略。在此背景下，美國2025年生效的關稅政策引入了新的變數，迫使相關人員重新評估採購來源、庫存策略和供應商多元化計畫。採購團隊越來越重視權衡短期成本影響與更近或替代供應來源的策略優勢之間的利弊，後者可以降低貿易政策波動帶來的風險。

全面的細分分析，闡述了應用、給藥途徑、最終用戶、通路、製劑形式和包裝形式的差異如何影響臨床應用和商業策略。

將產品開發、商業化和臨床實施策略與終端用戶的實際需求相匹配，需要對市場區隔動態有深刻的理解。從適應症的角度來看，碘化油注射既可用於診斷，也治療性介入。診斷應用包括肝臟影像和淋巴影像，而治療應用則著重於肝臟和淋巴治療。這種診斷和治療的雙重作用，使得產品配方和包裝必須具有獨特性，以滿足不同的停留時間、滲透性目標和操作要求。

決定關鍵全球市場部署路徑、採購模式和分銷選擇的區域性營運和監管觀點

區域趨勢對法規結構、採購行為和臨床實踐模式有顯著影響。相關人員必須考慮地域差異如何影響市場進入和供應鏈規劃。美洲地區面臨需求面壓力，包括先進介入放射學能力的集中、分散的醫院系統以及日益集中化的採購模式（傾向於大規模聯合採購協議）。同時，歐洲、中東和非洲地區（EMEA）的監管方式和醫療體系成熟度差異顯著，從高度集中的國家採購到分散的私營部門採購，以及對統一安全標準和跨境物流的日益重視，都體現了這一點。

影響碘化油注入供應環境和買家偏好的關鍵公司策略、生產能力和競爭優勢

競爭格局呈現出多元化的特點，既有成熟的專業造影劑生產商，也有正拓展造影劑領域的造影劑生產商，還有提供無菌灌裝和包裝服務的契約製造。市場參與企業透過配方穩定性、無菌保證、包裝創新以及在多種給藥途徑和臨床適應症中供給能力來脫穎而出。那些致力於產生臨床證據並進行嚴格的上市後監測的公司，已在臨床醫生和採購負責人中建立了牢固的信任，從而推動了產品在醫院和門診機構的應用。

為製造商和經銷商提供切實可行的、優先排序的建議，以提高在複雜供應鏈環境中的生產穩健性、臨床實施能力和分銷彈性。

產業領導者應採取重點舉措，加強供應連續性，提升臨床提案，並加速醫療機構的推廣應用。優先投資於無菌生產能力和品管系統，以降低供應風險並滿足日益嚴格的監管要求；同時評估區域製造地，以降低貿易政策風險並縮短關鍵客戶的前置作業時間。此外，還應制定預填充式注射器和管瓶的需求，並支援多劑量和單劑量使用場景，從而簡化庫存管理和流程。

為了獲得可靠的見解，我們採用嚴格的三角檢驗調查方法，結合對臨床醫生和採購負責人的初步訪談、監管審查、文獻檢驗和供應鏈分析。

本研究採用三角檢驗法進行綜合分析，該方法結合了訪談、監管和臨床文獻綜述以及供應鏈分析，以確保研究結果的可靠性和可操作性。主要研究包括對臨床醫生、醫院採購負責人、藥屋主任和供應鏈經理進行結構化訪談，以了解診斷和治療應用中的實際使用模式、採購限制和臨床偏好。這些定性資料與監管文件和產品標籤進行交叉核對，以檢驗安全性、給藥途徑指導和包裝限制。

簡要概述重點強調了製造品質、臨床證據、包裝創新和穩健的分銷網路等策略重點，以支持產品的持續推廣應用。

總之，碘化油注射仍然是一種臨床價值高、操作複雜的產品類型，需要不斷適應安全性、實證性和供應穩定性的新要求。其在診斷影像和標靶治療遞送方面的雙重作用，要求採用專門的配方、包裝和給藥策略，以滿足不同臨床環境的需求。先進影像技術的進步、監管力度的加強以及分銷模式的改變，共同凸顯了穩健的生產規範、區域性商業化策略以及採購中積極主動的風險緩解措施的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依給藥途徑分類的碘化油注射市場

  • 肌肉內注射
  • 靜脈注射

9. 依劑量數量分類的碘化油注射劑市場

  • 多劑量
  • 單一劑量

10. 依包裝類型分類的碘化油注射市場

  • 預填充式注射器
  • 管瓶

第11章 依應用分類的碘化油注射市場

  • 診斷
    • 肝臟影像
    • 造影
  • 治療
    • 肝臟治療
    • 淋巴療法

第12章 依最終用戶分類的碘化油注射市場

  • 門診治療中心
  • 診所
  • 診斷中心
  • 醫院

第13章 碘化油注射劑市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 碘化油注射劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 碘化油注射市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國碘化油注射劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國碘化油注射劑市場

第18章：中國碘油注射市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • BOC Sciences
  • DVM Global Exports LLP
  • Flagship Biotech International Pvt. Ltd.
  • Fujifilm Toyama Chemical
  • GE Healthcare
  • Glowria Lifecare
  • Guerbet
  • Infinium Pharmachem Limited
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Acebright Pharmaceuticals
  • Shanghai Wonder Pharmaceutical
  • Shanghai Zhongxi Sunve Pharmaceutical
  • Teva Pharmaceutical Industries
Product Code: MRR-4F7A6D4FF365

The Iodized Oil Injection Market was valued at USD 84.24 million in 2025 and is projected to grow to USD 96.06 million in 2026, with a CAGR of 12.17%, reaching USD 188.26 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 84.24 million
Estimated Year [2026] USD 96.06 million
Forecast Year [2032] USD 188.26 million
CAGR (%) 12.17%

A detailed introductory overview explaining clinical purpose, evolution, safety priorities, manufacturing considerations, and the operational relevance of iodized oil injection today

Iodized oil injection occupies a distinct niche at the intersection of diagnostic imaging and targeted therapeutic interventions, and its role continues to evolve alongside advances in imaging technology and interventional practice. Historically deployed as a radiopaque medium to enhance visualization of hepatic and lymphatic structures, the formulation's pharmacokinetic properties and radiodensity profile have made it useful both as a contrast agent and as a vehicle for localized therapeutic delivery. Clinicians and supply chain stakeholders alike must understand the interplay between clinical utility, administration paradigms, safety considerations, and manufacturing standards to navigate adoption and procurement decisions.

The clinical landscape is shaped by ongoing refinements in imaging modalities and interventional techniques, which have influenced how iodized oil is selected and administered. Concurrently, regulators and professional societies have emphasized patient safety, product quality, and clear labeling, prompting manufacturers to enhance quality-control measures and to invest in stability and packaging innovations. As a result, the product's relevance today extends beyond simple contrast enhancement, with increasing attention paid to administration route selection, compatibility with adjunct devices and delivery systems, and the procedural training required to optimize both diagnostic yield and therapeutic outcomes. This introduction sets the stage for deeper analysis of market dynamics, segmentation implications, regional variation, and strategic opportunities for stakeholders across the value chain.

Key technological, regulatory, and distribution shifts that are redefining clinical expectations, supply resilience, and product innovation for iodized oil injection

Several transformative shifts are reshaping the landscape for iodized oil injection, driven by technological innovation, regulatory recalibration, and a changing service delivery ecosystem. Advances in cross-sectional and interventional imaging have increased expectations for higher-fidelity contrast agents and more predictable distribution profiles, which in turn has focused attention on product purity, particle behavior, and compatibility with adjunctive interventional devices. As a consequence, manufacturers and clinical users are prioritizing formulations and packaging that support safer, more precise administration.

Regulatory bodies have elevated scrutiny on injectable contrast media and drug-device combinations, concentrating on sterility assurance, extractables and leachables, and post-market surveillance practices. This heightened oversight has prompted both legacy producers and new entrants to strengthen pharmacovigilance processes and to invest in clinical evidence generation. At the same time, distribution models are shifting toward more integrated and digitally enabled channels, including expanded online pharmacy options and centralized procurement within hospital networks, which affects how products are stocked, traced, and replenished. These converging trends are encouraging innovation across product variants and delivery formats while raising the bar for compliance and supply-chain resilience, ultimately changing how clinicians, payers, and procurement teams evaluate iodized oil injection solutions.

Assessing the cumulative operational and procurement consequences of recent United States tariff actions on sourcing strategies, inventory resilience, and supplier diversification

Tariff policies and trade measures introduced in recent years have had ripple effects across medical product supply chains, influencing sourcing decisions, pricing negotiation dynamics, and regional manufacturing strategies. Within this broader context, tariffs implemented in the United States in 2025 have introduced a new variable that compels stakeholders to reassess procurement sourcing, inventory strategies, and supplier diversification plans. Procurement teams are increasingly weighing the trade-offs between near-term cost impacts and the strategic advantages of closer or alternative supply arrangements that can mitigate exposure to trade-policy volatility.

In response, manufacturers and distributors are exploring a range of tactical responses including regional manufacturing adjustments, amendments to contractual incoterms, and enhanced hedging practices in procurement. Clinical users and hospital supply managers are similarly adapting by expanding approved vendor lists, consolidating purchase schedules to minimize transaction costs, and increasing coordination with group purchasing organizations to optimize leverage. While tariffs present short-term operational friction, they are also accelerating conversations about supply-chain transparency, localization of critical packaging and sterile-filling capabilities, and the need for contingency planning to maintain uninterrupted access to essential injectable products. Taken together, these adaptations reflect a sector-wide pivot toward more resilient sourcing and inventory practices that prioritize clinical continuity.

Comprehensive segmentation insights explaining how application, route, end user, distribution, formulation, and packaging distinctions shape clinical adoption and commercial strategy

A nuanced understanding of segmentation dynamics is required to align product development, commercialization, and clinical adoption strategies to the real-world needs of end users. When the market is viewed through the lens of application, iodized oil injection serves both diagnostic purposes and therapeutic interventions: diagnostic applications encompass hepatic imaging and lymphatic imaging, whereas therapeutic uses focus on hepatic treatment and lymphatic treatment. This dual diagnostic-therapeutic role necessitates distinct formulation and packaging considerations to support differing dwell times, radiopacity targets, and procedural handling requirements.

Administration route segmentation highlights the operational and clinical differences between intramuscular and intravenous use, with each route presenting unique requirements for viscosity, injection technique, and post-procedural monitoring. End-user segmentation underscores variable purchasing pathways and usage patterns across ambulatory care centers, clinics, diagnostic centers, and hospitals, each of which has distinct inventory management practices, clinician training profiles, and procurement constraints. Distribution channel segmentation captures the evolving mix between hospital pharmacy, online pharmacy, and retail pharmacy channels, influencing how products are marketed, regulated, and replenished. Product-variant considerations such as multi dose versus single dose formulations affect sterility controls, labeling, and inventory turnover, while packaging segmentation-prefilled syringe versus vial-has direct implications for ease of use in procedural settings, waste management, and compatibility with administration devices. Understanding these interwoven segments helps manufacturers and supply-chain stakeholders prioritize investments in formulation, packaging, and commercial strategy to meet differentiated clinical and operational needs.

Region-specific operational and regulatory perspectives that determine adoption pathways, procurement models, and distribution choices across major global markets

Regional dynamics materially influence regulatory frameworks, procurement behavior, and clinical practice patterns, and stakeholders must consider how geographic variation shapes market access and supply-chain planning. In the Americas, demand-side pressures are informed by concentrated advanced interventional radiology capabilities, distributed hospital systems, and evolving procurement centralization that favors larger group purchasing arrangements. Meanwhile, Europe, Middle East & Africa encompasses a wide spectrum of regulatory approaches and health system maturities, from highly centralized national procurement to fragmented private-sector purchasing, and the region is characterized by a focus on harmonized safety standards and cross-border distribution logistics.

In Asia-Pacific, rapid modernization of tertiary care centers, expanding interventional radiology capacity, and a growing emphasis on domestic manufacturing capabilities drive unique adoption pathways and supplier strategies. Across all regions, differences in reimbursement structures, clinical guidelines, and sterilization and packaging infrastructure influence which product variants and packaging configurations become preferred. Consequently, manufacturers and distributors need region-specific commercialization tactics that align regulatory filings, clinician education, and distribution partnerships with local operational realities, while ensuring that supply continuity and pharmacovigilance commitments meet the expectations of diverse health systems.

Critical corporate strategies, manufacturing capabilities, and competitive differentiators shaping the iodized oil injection supplier landscape and buyer preferences

The competitive landscape is characterized by a mix of established specialty radiopaque product manufacturers, injectable pharmaceutical producers that have expanded into contrast media, and contract manufacturers that provide sterile filling and packaging services. Market participants differentiate on the basis of formulation stability, sterility assurance, packaging innovation, and the ability to supply consistent quality across multiple administration routes and clinical indications. Firms that invest in clinical evidence generation and that maintain rigorous post-market surveillance practices tend to build stronger trust among clinicians and procurement professionals, thereby easing adoption in hospital and ambulatory settings.

Strategic behaviors observed among leading players include vertical integration of sterile manufacturing capabilities, selective licensing agreements to expand geographic reach, and partnerships with distributors that have deep hospital pharmacy relationships. Additionally, innovation efforts focus on improving handling characteristics, reducing risk of contamination, and developing packaging formats that minimize preparation time in procedural suites. Companies that proactively address regulatory compliance, streamline logistics for cold-chain or sterile products, and offer robust training and educational support for clinicians typically gain competitive advantage. These combined factors shape buyer preferences and create barriers to entry for new entrants without demonstrable manufacturing rigor or regulatory track record.

Practical and prioritized recommendations for manufacturers and distributors to enhance manufacturing robustness, clinical adoption, and distribution resilience in a complex supply environment

Industry leaders should pursue targeted actions that strengthen supply continuity, enhance clinical value propositions, and accelerate adoption across care settings. Prioritize investments in sterile manufacturing capacity and quality management systems to reduce supply risk and to meet elevated regulatory expectations, while simultaneously evaluating regional manufacturing footprints to mitigate trade-policy exposure and to shorten lead times for key customers. Complement manufacturing investments with a clear packaging strategy that addresses clinical preferences for prefilled syringes or vials and that supports multi dose and single dose use cases to simplify inventory and procedural workflows.

On the commercial front, develop evidence-generation programs that quantify clinical benefits for both diagnostic and therapeutic applications, and tailor educational initiatives to the needs of hospitals, diagnostic centers, clinics, and ambulatory care centers. Strengthen distribution resilience by diversifying channel partnerships across hospital pharmacy, online pharmacy, and retail pharmacy networks, and by implementing digital order management tools that increase transparency and responsiveness. Finally, align product development priorities with administration-route requirements for intramuscular versus intravenous use, ensuring compatibility with standard administration devices and training materials that reduce procedural variability. These measures will collectively enhance market credibility, reduce operational friction, and position organizations to respond rapidly to shifts in clinical practice and policy environments.

A rigorous triangulated research methodology integrating primary clinician and procurement interviews, regulatory review, literature validation, and supply-chain analysis for high-confidence insights

This research synthesis is founded on a triangulated methodology combining primary interviews, regulatory and clinical literature review, and supply-chain analysis to ensure reliable and actionable insights. Primary research included structured interviews with clinicians, hospital procurement officers, pharmacy directors, and supply-chain managers to capture real-world usage patterns, procurement constraints, and clinical preferences across diagnostic and therapeutic applications. These qualitative inputs were cross-referenced with regulatory documentation and product labeling to verify safety, administration-route guidance, and packaging constraints.

Complementary secondary research encompassed peer-reviewed clinical studies, procedural guidelines, and public regulatory filings to validate clinical use cases and to identify prevailing standards for sterility and labeling. Supply-chain mapping assessed manufacturing footprints, sterile-filling capabilities, packaging suppliers, and distribution pathways to identify common bottlenecks and resilience measures. Where appropriate, findings were corroborated through follow-up validation interviews and document reviews to ensure consistency and to reduce the risk of single-source bias. Together, these methods provide a robust foundation for the insights and recommendations presented, emphasizing transparency, reproducibility, and relevance to decision-makers across clinical, commercial, and procurement functions.

A succinct concluding synthesis emphasizing strategic priorities for manufacturing quality, clinical evidence, packaging innovation, and resilient distribution to support sustained adoption

In conclusion, iodized oil injection remains a clinically valuable and operationally nuanced product category that is adapting to new expectations for safety, evidence, and supply resilience. Its dual role in diagnostic imaging and targeted therapeutic delivery demands tailored formulation, packaging, and administration strategies to meet the needs of diverse clinical settings. The convergence of advanced imaging capabilities, stricter regulatory oversight, and evolving distribution models has elevated the importance of robust manufacturing practices, regionally attuned commercialization tactics, and proactive risk mitigation in procurement.

Moving forward, stakeholders who invest selectively in sterile manufacturing capacity, embrace packaging innovations that streamline procedural workflows, and generate targeted clinical evidence will be better positioned to meet clinician and purchaser expectations. At the same time, organizations that diversify distribution channels and prepare contingency sourcing plans will reduce exposure to policy and trade-related disruptions. Taken together, these strategic priorities form a coherent pathway for sustaining product availability, improving patient outcomes, and supporting long-term adoption across hospitals, diagnostic centers, clinics, and ambulatory care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Iodized Oil Injection Market, by Administration Route

  • 8.1. Intramuscular
  • 8.2. Intravenous

9. Iodized Oil Injection Market, by Product Variant

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Iodized Oil Injection Market, by Packaging

  • 10.1. Prefilled Syringe
  • 10.2. Vial

11. Iodized Oil Injection Market, by Application

  • 11.1. Diagnostic
    • 11.1.1. Hepatic Imaging
    • 11.1.2. Lymphatic Imaging
  • 11.2. Therapeutic
    • 11.2.1. Hepatic Treatment
    • 11.2.2. Lymphatic Treatment

12. Iodized Oil Injection Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals

13. Iodized Oil Injection Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Iodized Oil Injection Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Iodized Oil Injection Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Iodized Oil Injection Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Iodized Oil Injection Market

18. China Iodized Oil Injection Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Biophore India Pharmaceuticals Pvt. Ltd.
  • 19.6. BOC Sciences
  • 19.7. DVM Global Exports LLP
  • 19.8. Flagship Biotech International Pvt. Ltd.
  • 19.9. Fujifilm Toyama Chemical
  • 19.10. GE Healthcare
  • 19.11. Glowria Lifecare
  • 19.12. Guerbet
  • 19.13. Infinium Pharmachem Limited
  • 19.14. Jiangsu Hengrui Pharmaceuticals
  • 19.15. Shanghai Acebright Pharmaceuticals
  • 19.16. Shanghai Wonder Pharmaceutical
  • 19.17. Shanghai Zhongxi Sunve Pharmaceutical
  • 19.18. Teva Pharmaceutical Industries

LIST OF FIGURES

  • FIGURE 1. GLOBAL IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IODIZED OIL INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IODIZED OIL INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 153. GCC IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 154. GCC IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 156. GCC IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 157. GCC IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 180. G7 IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 181. G7 IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 189. NATO IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 190. NATO IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)